Newsletter No. 97 -- October 2007
NETWORK FOR TRANSLATIONAL RESEARCH (NTR): OPTICAL IMAGING IN MULTIMODAL PLATFORMS (U54) (NCI) (RFA-CA-08-002)
Release Date: October 12, 2007
Letters of Intent Receipt Date: December 24, 2007
Application Receipt Date: January 24, 2008
This Funding Opportunity Announcement (FOA) issued by the Cancer Imaging Program of the NCI is an open competition initiative, designed to continue the efforts of the NCI to develop and translate cancer-relevant optical imaging technologies as a part of an overall imaging program for early cancer detection, diagnosis, therapeutic response, drug development, and image-guided therapy. This FOA stems from the previous initiative on optical imaging technology, but the program structure and goals of the current FOA differ from those of the original program. Accordingly, all responses to this FOA will be considered new applications, with the main objective being to accelerate the translational research of in vivo multimodal imaging and/or spectroscopic platforms from the laboratory and pre-clinical level to the clinical level. Applications are sought from multi-disciplinary, multi-institutional research teams. After the awards, successful teams will become Centers that will be organized into an interactive network. The network will be called the "Network for Translational Research: Optical Imaging" (NTR). The purpose of NTR is to develop, optimize, and validate imaging technology platforms and methods so that they can enter single or multi-site clinical trials and eventually be incorporated into clinical practice. Applicants responding to this FOA must identify a specific cancer-relevant clinical goal and propose to develop and validate at least one multimodal imaging platform, as defined in this FOA, to address this clinical goal.
INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARD (U54)(RFA-RM-07-007) (Reissue of RFA-RM-07-002)
Letters of Intent Receipt Date(s): Sept 24, 2007 (Extended to Oct 9, 2007 per NOT-RM-07-013)
Application Receipt Date(s): Oct 24, 2007 (Extended to Nov 7, 2007 per NOT-RM-07-013)
Expiration Date: Oct 25, 2007 (Extended to Nov 8, 2007 per NOT-RM-07-013)
The purpose of this initiative is to assist institutions to create a uniquely transformative, novel, and integrative academic home for Clinical and Translational Science that has the resources to train and advance a cadre of well-trained multi- and inter-disciplinary investigators and research teams with access to innovative research tools and information technologies to promote the application of new knowledge and techniques to patient care. Clinical and Translational Science Awards (CTSAs) will attract basic, translational, and clinical investigators, community clinicians, clinical practices, networks, professional societies, and industry to develop new professional interactions, programs, and research projects. Through innovative advanced degree programs, CTSAs will foster a new discipline of Clinical and Translational Science that will be much broader and deeper than their separate components.
MULTIDISCIPLINARY FELLOWSHIPS IN CANCER NANOTECHNOLOGY RESEARCH (F32 AND F33) (NCI) (RFA-CA-08-003)
Application Receipt Date: December 20, 2007
This Funding Opportunity Announcement (FOA) is designed to support the multidisciplinary training of individuals with background in the basic, biomedical, clinical, and information sciences and/or engineering who are pursuing research that applies the development and application of nanotechnology to the prevention, detection, diagnosis, and/or treatment of cancer. This FOA solicits applications for postdoctoral fellowships from recent doctoral level graduates as well as applications for senior fellowships from candidates with at least 7 years of research experience beyond the doctorate and established independent research positions. The term "nanotechnology", as used in this FOA, refers to devices or base materials that are less than 1000 nm in size (although the assembly, synthesis, and/or fabrication of components at dimensions less than 300 nm should be demonstrated) and may incorporate synthetic materials or biomaterials engineered to provide novel properties or modified functions based on nanoscale size, i.e., nanomaterials. This FOA is a component of the NCI Alliance for Nanotechnology in Cancer (http://nano.cancer.gov/), an integrated 5-year-long initiative to develop and apply nanotechnology to cancer prevention, detection, diagnosis, and treatment, thereby enabling nanotechnology to become a fundamental driver of advances in cancer research and clinical oncology.
LYMPHATIC BIOLOGY IN HEALTH AND DISEASE (R01) (NCI, NHLBI, NICHD, NIDDK, NINR) (PAR-07-420)
Letters of Intent Receipt Date(s): August 27, 2007, August 16, 2008, August 17, 2009
Application Receipt Dates: September 28, 2007, September 18, 2008, September 18, 2009
The lymphatic system is an important component of the circulation, participating in both the homeostatic control of interstitial fluid volume and composition, the immune functions of cellular trafficking, and absorption of dietary lipids from the gut. When these functions become distorted through inherited or acquired disease, a broad array of pathological dysfunctions can be encountered, encompassing such manifestations as primary and secondary lymphedema, lymphatic and complex vascular malformations, cancer growth and metastases, acute and chronic inflammation and infection, and various metabolic derangements. In view of the limited attention currently given to the biology and pathobiology of the lymphatic system, the participating institutes are interested in approaches that will identify the developmental, molecular, and cellular defects that contribute to the health and disease of the lymphatic system. Examples of potential areas of research pertinent to NCI participation in PAR-07-420 are listed in the announcements. Among the examples are a) Molecular characterization and comparison of normal and tumor lymphatic endothelia and their component cells, including identifications of molecular markers, secreted factors, and/or receptors;b) Determination of the functional status of tumor lymphatic vessels, e.g. the uptake and transport of fluid and macromolecules; c)Study of the interplay between angiogenesis and lymphangiogenesis; d) Design and validation of imaging modalities to visualize normal and tumor lymphatics.
NCI Participation URL: http://grants.nih.gov/grants/guide/notice-files/NOT-CA-07-022.html
EXTRAMURAL CLINICAL RESEARCH LOAN REPAYMENT PROGRAM FOR INDIVIDUALS FROM DISADVANTAGED BACKGROUNDS (LRP) (NCMHD) (PA-07-441)
Application Period: September 1 to December 1, 2007.
The NIH and the NCMHD announce the availability of educational loan repayment under the Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (ECR -LRP or Program). The ECR-LRP provides for the repayment of educational loan debt of up to $35,000 annually for qualified health professionals from disadvantaged backgrounds conducting clinical research for domestic non-profit or government entities.
EXTRAMURAL LOAN REPAYMENT PROGRAM FOR CLINICAL RESEARCHERS (LRP) (PA-07-442)
Application Period: September 1 to December 1, 2007.
The National Institutes of Health (NIH) announces the availability of educational loan repayment under the NIH Extramural Loan Repayment Program for Clinical Researchers (LRP-CR). The Loan Repayment Program for Clinical Researchers provides for the repayment of up to $35,000 of the principal and interest of the extant educational loans of such health professionals for each year of obligated service.
CIP DCIDE PROGRAM
The Cancer Imaging Program of the NCI requests submissions for its Development of Clinical Imaging Drugs and Enhancers (DCIDE) initiative. The goal is the rapid movement of promising, novel cancer imaging enhancers or molecular probes from the laboratory to proof of principle clinical trials. See the web site for details.
EXTENDED COMMENT PERIOD FOR THE REQUEST FOR INFORMATION ON THE NIH SYSTEM TO SUPPORT BIOMEDICAL AND BEHAVIORAL RESEARCH AND PEER REVIEW (NOT-OD-07-084)
Deadline for response: September 7, 2007
GUEST AUTHOR OPPORTUNITIES IN THE NIH MICAD DATABASE
The Molecular Imaging and Contrast Agent Database (MICAD) program has been developed as a key component of the NIH Molecular Imaging Roadmap to provide freely accessible online scientific information on in vivo molecular imaging and contrast agents. To accelerate expansion of the database to include all published agents, the MICAD program has implemented a procedure for members of the imaging community to write and submit entries (chapters) as guest authors to the database. All members of the imaging community are encouraged to consider this guest author opportunities. For further information, please contact the MICAD staff at email@example.com. Individual guest authors will be provide with detailed instructions, style guidelines, and a chapter template. The name of the contributing author(s) will be acknowledged and included in the MICAD online publication.
Vascular Imaging and Therapeutic Targeting in Cancer
October 16-17, 2007, Dallas, TX
Advances in Ultrasound - 17th Annual Meeting, Society of Radiologists in Ultrasound
October 26-28, 2007, Chicago, IL
4th Annual Memphis BioImaging Conference
November 1-2, 2007, Fogelman Executive Conference Center, Memphis, TN
SIXTH INTERNATIONAL CONFERENCE ON THE ULTRASONIC MEASUREMENT AND IMAGING OF TISSUE ELASTICITY
November 2-5, 2007, Eldorado Hotel and Spa, Santa Fe, New Mexico
SMALL ANIMAL IMAGING WORKSHOP AT STANFORD
November 7-10, 2007, Clark Center, Stanford University, Stanford, California
RSNA 2007 - See us in Hall A, Booth 1101
November 25 - 30, 2007, McCormick Place, Chicago, IL
January 17-19, 2008, Bethesda North Convention Center, Rockville, MD
ISMRM 16th Scientific Meeting & Exhibition, Toronto, ON, Canada
May 3-9, 2008, Toronto, ON, Canada.
If you wish to remain on the list, no action is necessary. If you wish to be added to the list, please contact Dr Barbara Croft by return e-mail (firstname.lastname@example.org). Please include your complete mailing address, title, phone and fax numbers.
Cancer Imaging Program,
Division of Cancer Treatment and Diagnosis,
NCI 6130 Executive Boulevard - MSC-7412
Bethesda, MD 20892-7412
Tel: 301 496 9531
Fax: 301 480 3507